BOSTON, July 15 /PRNewswire/ -- Riverside Partners, a Boston based private equity firm focusing on healthcare and technology businesses, is pleased to announce that The J-Pac and Doyen Medipharm Group (“JPDM” or the “Company”), a leader in contract manufacturing and packaging machinery for the medical device and pharmaceutical industries, has named Dr. P. Richard Eagling as the Company’s new Chief Executive Officer and a board member. Richard succeeds Bill McLaughlin, who led JPDM successfully for the past 8 years. Mr. McLaughlin will remain active with the Group as its Vice Chairman and a member of the board of directors.
Dr. Eagling brings to J-Pac and Doyen Medipharm 30 years of industry experience in the medical device, diagnostic, life science and biopharmaceutical fields. Dr. Eagling has been responsible for leading large divisions of several companies including Ciba Corning Diagnostics, Oridion Medical, Integrated Biosystems and most recently Stedim Biosystems. Additionally, Dr. Eagling previously served as the President and CEO of Gamera Bioscience.
“We believe Richard’s experience and proven success with global companies, working in organizations both larger and smaller than J-Pac, will help us continue to capitalize on the tremendous opportunities for growth ahead of us. We are sure that his commitment, integrity, and interpersonal style will fit extremely well with the culture and values of our entire team,” said Brian Guthrie, a General Partner at Riverside Partners and Chairman of the Board of J-Pac.
“I am extremely excited to build upon the great medical manufacturing platform that Bill McLaughlin and his team has created at J-Pac and Doyen Medipharm and am looking forward to leading the Company’s next phase of growth. We will continue to focus on providing high quality advanced drug delivery and related medical products to the world’s leading OEMs,” said Dr. Eagling.
About J-Pac and Doyen Manufacturing
Headquartered in Somersworth, NH, J-Pac is a leading contract manufacturer and equipment maker for medical device and biopharmaceutical OEMs. J-Pac’s contract manufacturing division specializes in medical devices, medical packaging and trays, and advanced medical device and drug delivery systems. Through its Doyen Division, J-Pac also provides precision high-volume production equipment to medical device and biopharmaceutical OEMs around the world.
About Riverside Partners
Founded in 1989, Riverside Partners is a middle market private equity firm currently investing Riverside Fund III, L.P. The fund focuses on growth-oriented companies in the healthcare and technology industries. Riverside is particularly experienced at partnering with founders, owners and management teams and it brings substantial domain expertise and operating experience to its portfolio companies. The partners at Riverside have managed more than $500 million in investments in over 50 companies. We are currently focused on companies with revenues between $20 - $200 million and with $5 - $25 million of EBITDA.
CONTACT: Jon Lemelman, General Partner of Riverside Partners, LLC,
+1-617-351-2810, jlemelman@riversidepartners.com
Web site: http://www.riversidepartners.com/
